CN110237166A - 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 - Google Patents
一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 Download PDFInfo
- Publication number
- CN110237166A CN110237166A CN201910338069.8A CN201910338069A CN110237166A CN 110237166 A CN110237166 A CN 110237166A CN 201910338069 A CN201910338069 A CN 201910338069A CN 110237166 A CN110237166 A CN 110237166A
- Authority
- CN
- China
- Prior art keywords
- extract
- liver function
- preparation
- preventing bone
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 54
- 230000003908 liver function Effects 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 26
- 239000000284 extract Substances 0.000 claims abstract description 140
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 32
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 32
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 29
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 29
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 29
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 27
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 23
- 241000202726 Bupleurum Species 0.000 claims abstract description 21
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 20
- 229940010454 licorice Drugs 0.000 claims abstract description 20
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 11
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 11
- 230000007423 decrease Effects 0.000 claims abstract description 8
- 230000037182 bone density Effects 0.000 claims abstract description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims abstract description 5
- 108010082126 Alanine transaminase Proteins 0.000 claims abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 108010088751 Albumins Proteins 0.000 claims abstract description 4
- 102000005686 Serum Globulins Human genes 0.000 claims abstract description 4
- 108010045362 Serum Globulins Proteins 0.000 claims abstract description 4
- 244000061520 Angelica archangelica Species 0.000 claims abstract 6
- 102000009027 Albumins Human genes 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 238000000605 extraction Methods 0.000 claims description 31
- 235000019441 ethanol Nutrition 0.000 claims description 28
- 230000002829 reductive effect Effects 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 241000202807 Glycyrrhiza Species 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 17
- 239000012153 distilled water Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 claims description 5
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 claims description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 9
- 239000011575 calcium Substances 0.000 abstract description 9
- 229910052791 calcium Inorganic materials 0.000 abstract description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 5
- 239000011574 phosphorus Substances 0.000 abstract description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 241000700159 Rattus Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 8
- 102100027211 Albumin Human genes 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010019837 Hepatocellular injury Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 231100000437 hepatocellular injury Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- 235000010209 hesperetin Nutrition 0.000 description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001148782 Davallia Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101001023770 Homo sapiens Transcription factor NF-E2 45 kDa subunit Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100035412 Transcription factor NF-E2 45 kDa subunit Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000009040 gushukang Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种可改善肝功能并预防骨质疏松的天然组合物,由柴胡提取物、当归提取物、香附提取物、陈皮提取物、栀子提取物、玛咖提取物和甘草提取物组成,各组分的有效成分相互配合,可抑制血清球蛋白、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶(AST)上升和白蛋白下降,改善肝功能,并可提高骨密度、骨钙和骨磷等骨矿物质含量,起到缓解骨质疏松效果。
Description
技术领域
本发明属于天然组合物技术领域,具体涉及一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法。
背景技术
骨质疏松症(osteoporosis,OP)是一种以骨量低,骨组织微结构损坏,易发生骨折为特征的全身性骨病。骨质疏松可发生于任何年龄,但多见于绝经后女性和老年男性,据估算我国骨质疏松症患者近7 000万,骨量减少患者已超过 2亿人。骨质疏松性骨折的危害巨大,是老年患者致残和致死的主要原因之一。而且,骨质疏松症及骨折的医疗和护理,需要投入大量的人力、物力和财力,造成沉重的家庭和社会负担。据预测,我国2035和2050年用于主要骨质疏松性骨折(腕部、椎体和髋部)的医疗费用将分别高达1320亿元和1630亿元。随着我国人口老龄化的到来,骨质疏松症已成为我国面临的重要公共健康问题。
多方面因素导致了骨质疏松症的发生,除老龄、女性绝经这些固有危险因素外,长期服用具有影响骨代谢疾病或使用影响骨代谢药物,钙或维生素 D缺乏、性腺功能低下、体力活动缺乏、体重过低、饮食中营养失衡、吸烟、过度饮酒或咖啡等非固有危险因素也会导致骨质疏松。
通过调查慢性肝病患者骨质疏松的发生率,并与正常人群作对比,发现慢性乙型肝炎、病毒性肝炎、肝硬化和肝癌患者的骨质疏松发生率均明显升高,并随着肝功能损害的加重,发生率逐步升高,其机制可能与血钙下降、血甲状旁腺激素水平升高有关。有研究认为骨质疏松症是慢性肝病常见的并发症,肝病导致骨形成不足主要机制是由于肝功能异常产生有害物质的影响,如过多的胆红素、胆汁酸或酒精的毒性作用。关于肝在骨质疏松症中的发生发展机制,现代医学认为肝主要通过维生素D及钙、磷代谢、雌激素等途径影响骨形成与骨吸收。
目前用于抗骨质疏松的药物主要有维生素D和钙剂等基础膳食补充剂、雌激素类药物、双膦酸盐、降钙素和中药制剂等。雌激素、双膦酸盐和降钙素等药物虽然临床疗效较好,但长期使用具有较大不良反应。临床常用的中药制剂有金匮肾气丸、骨疏康胶囊、知柏地黄丸、仙灵骨葆胶囊、六味地黄丸和强骨胶囊等,其中的主要单方成分为淫羊藿、熟地黄、骨碎补、山药、山茱萸、丹参和枸杞等,但这些产品多只考虑解决骨质疏松症状,而未考虑解决导致骨质疏松的原因;或简单认为骨质疏松由肾虚引起,以补肾为主,未考虑其他因素原因。因此,长期慢性肝病患者的肝功能异常状况极易导致并发骨质疏松,其急需既能改善肝功能又能预防骨质疏松发生的健康功能产品。
发明内容
有鉴于此,本发明提供了一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法。
本发明第一方面提供了一种可改善肝功能并预防骨质疏松的天然组合物,组分包括:以质量百分比计,柴胡提取物10~20%、当归提取物10-20%、香附提取物10~20%、陈皮提取物5~15%、栀子提取物5~15%、玛咖提取物10~20%和甘草提取物5~15%。
优选的,所述柴胡提取物中柴胡皂苷含量≥100mg/g;所述当归提取物中当归多糖含量≥200mg/g;所述香附提取物中多糖含量≥200mg/g;所述陈皮提取物中总黄酮含量≥50mg/g;所述栀子提取物中栀子苷含量≥100mg/g;所述玛咖提取物中玛咖酰胺含量≥40mg/g;所述甘草提取物中甘草酸含量≥400mg/g。
本发明第二方面提供了上述可改善肝功能并预防骨质疏松的中药组合物的制备方法,步骤包括:以柴胡、当归、香附、陈皮、栀子、玛咖和甘草为原料,对原料分别进行提取,将提取得到的柴胡提取物、当归提取物、香附提取物、陈皮提取物、栀子提取物、玛咖提取物和甘草提取物按比例混合。
优选的,所述柴胡提取物的提取方法包括:取干燥的柴胡,与水以质量体积比1:8~10的比例混合,40~50℃回流提取3~5小时,水提取液减压浓缩成膏状,用乙醇溶解,减压浓缩干燥即得柴胡提取物。
更加优选的,在上述柴胡提取物的提取过程中,所述乙醇为体积百分数60%乙醇。
优选的,所述当归提取物的提取方法包括:取干燥的当归,粉碎,与蒸馏水以质量体积比1:5~10的比例混合,70~90℃回流提取3~5小时,提取液减压浓缩至1/9~1/11体积,加入乙醇至醇浓度为65%,过滤后收集滤渣,干燥即得当归提取物。
更加优选的,在上述当归提取物的提取过程中,所述提取液减压浓缩至1/10体积。
更加优选的,在上述当归提取物的提取过程中,所述乙醇为体积百分数95%乙醇。
优选的,所述香附提取物的提取方法包括:取干燥的香附,粉碎,与水以质量体积比1:5~10的比例浸泡2~3h,50~70℃回流提取3~5小时,减压浓缩后干燥即得香附提取物。
优选的,所述陈皮提取物的提取方法包括:将陈皮与乙醇以质量体积比1:5~10的比例混合,70~90℃回流提取2~4小时,加入等体积乙酸乙酯萃取,所得乙酸乙酯相减压浓缩,干燥后即得陈皮提取物。
优选的,所述栀子提取物的提取方法包括:取栀子果实粉末,加石油醚在88~92℃下浸泡22~26h脱脂,过滤后滤渣与乙醇以质量体积比1:5~10的比例混合,回流提取3~5h,减压浓缩得浸膏,浸膏用蒸馏水溶解,搅拌,静置 2~4h,过滤,所得上清液减压浓缩干燥后即得栀子提取物。
更加优选的,在上述栀子提取物的提取过程中,取栀子果实粉末,加石油醚在90℃下浸泡24h脱脂。
更加优选的,在上述栀子提取物的提取过程中,所述乙醇为体积百分数95%乙醇。
更加优选的,在上述栀子提取物的提取过程中,所述浸膏用蒸馏水溶解,搅拌,静置3h后过滤。
优选的,所述玛咖提取物的提取方法包括:取干燥的玛咖,与乙醇以质量体积比1:5~10的比例混合,超声提取2~4小时,醇提取液于45~55℃减压浓缩得浸膏,浸膏干燥即得玛咖提取物。
更加优选的,在上述玛咖提取物的提取过程中,所述纯提液于50℃减压浓缩得浸膏。
优选的,所述甘草提取物的提取方法包括:取干燥的甘草,与蒸馏水以质量体积比1:9~11的比例混合,88~92℃回流提取3.5~4.5小时,提取液浓缩至原体积的1/4~1/6,过滤,滤液加浓盐酸调pH至2~4,静置7~9小时,过滤,滤渣用适量蒸馏水洗涤,滤渣干燥即得甘草提取物。
更加优选的,所述甘草与蒸馏水以质量体积比1:10的比例混合,90℃回流提取4小时,提取液浓缩至原体积的1/5,过滤,滤液加浓盐酸调pH至3,静置8小时,过滤,滤渣用适量蒸馏水洗涤两次,滤渣干燥即得甘草提取物。
本发明第三方面提供了上述可改善肝功能并预防骨质疏松的中药组合物在制备改善肝功能并预防骨质疏松症药物中的应用,所述可改善肝功能并预防骨质疏松药物用于抑制血清球蛋白、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶上升和白蛋白下降,提高骨密度、骨矿物质含量。
本发明中各主要原料的功效活性如下:
1.柴胡通过显著抑制肝脏中的IL-1、TNF-α、TGF-β1、ɑ-SMA的基因表达和HSC、脂质过氧化物的生成来治疗肝纤维化。此外,柴胡还能减少肝细胞损伤与坏死,改善肝功能,促进肝脏脂质降解,抑制其在细胞外基质积累而降低肝硬化的发病率,提高肝癌患者的生存率。柴胡皂苷是柴胡中的主要活性成分,其可下调BMP-4表达,抑制肝星状细胞活化,并具有抑制乙肝病毒DNA 复制的活性。
2.当归中的活性成分当归多糖可减轻肝、肾细胞水肿,增加肝、肾组织中的超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)活性,减少丙二醛 (MDA)、过氧化脂(LPO)含量,该作用是通过抑制肝星状细胞Ⅲ型胶原分泌、转化生长因子β1(TGF-β1)Ⅰ型和Ⅱ型受体以及NF-E2相关因子2(Nrf2)蛋白表达,促进磷酸化糖原合成酶激酶3β(p-GSK-3β)蛋白表达来产生的。同时,当归多糖还可抑制Wnt/β-catenin信号通路的过度激活,调节骨代谢平衡,改善骨质疏松。
3.香附中的香附多糖具有较好的保肝及抑制肝纤维化的活性,该效果主要是通过增加肝细胞膜通透性,改善血清基质金属蛋白酶2(MMP-2)/组织金属蛋白酶抑制剂-2(TIMP-2)失衡和降低转化生长因子-β1水平实现的。4.陈皮中的陈皮素等黄酮类物质具有降低总胆固醇(total cholesterol,TC)、甘油三酯 (triglyceride,TG)和低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C) 水平作用,同时可降低血清中谷草转氨酶和谷丙转氨酶水平,改善肝脏脂肪变性情况,抑制肝脏炎症因子释放,减轻肝脏肝细胞水肿、坏死和抑制炎性细胞浸润, 减少肝酶的释放,陈皮素对肝损伤的保护作用与抑制肝细胞MAPK(ERK、JNK 和p38MAPK)信号通路过度活化、减少炎症介质iNOS和COX-2的表达和激活 Nrf2-HO-1抗氧化通路有关。
5.栀子中的栀子苷对各种急慢性肝损伤均具有明显的保肝疗效,其机制与栀子苷调节胆汁酸胆红素代谢、增强肝组织脂质代谢水平、提高抗氧化酶体系活力、抑制氧化应激反应及炎性因子表达相关。
6.玛咖可促进成骨细胞增殖、提高股骨和脊椎骨密度、改善骨组织物理参数和形态结构。玛咖酰胺是玛咖中主要活性成分,其可通过提高雌激素受体表达和成骨关键因子骨形态发生蛋白2、核心结合因子1、I型胶原和碱性磷酸酶的表达,促进骨形成过程;抑制病理状态下雌激素水平降低和抗酒石酸性磷酸酶活性上升,抑制骨吸收过程,最终起到抗骨质疏松作用。
7.甘草中的甘草酸通过下调核受体超家族转录因子γ(PPAR-γ)、核转录因子SREBP-1、固醇调节元件结合蛋白裂解激活蛋白SCAP的表达,缓解肝细胞炎症,改善肝组织中抗氧化酶活性、提高机体自由基清除能力,降低氧化应激损伤及细胞质膜的脂质过氧化水平,从而修复细胞质膜,降低肝损伤。同时,其可促进碱性磷酸酶、雌二醇的分泌,减少骨的重吸收,促进骨钙及骨矿物形成,造成骨盐沉积的增加而拮抗骨质疏松。
与现有技术相比,本发明的有益效果是:本发明提供的可改善肝功能并预防骨质疏松的天然组合物,由柴胡提取物、当归提取物、香附提取物、陈皮提取物、栀子提取物、玛咖提取物、甘草提取物组成,各组分的有效成分相互配合,可抑制血清球蛋白、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶上升和白蛋白下降,改善肝功能,并可提高骨密度、骨钙和骨磷等骨矿物质含量,起到缓解骨质疏松效果。
具体实施方式
为了便于理解本发明,下文将结合实施例对本发明作更全面、细致地描述,但本发明的保护范围并不限于以下具体的实施例。
除非另有定义,下文中所使用的所有专业术语与本领域技术人员通常理解的含义相同。本文中所使用的专业术语只是为了描述具体实施例的目的,并不是旨在限制本发明的保护范围。
除非另有特别说明,本发明中用到的各种原材料、试剂、仪器和设备等,均可通过市场购买得到或者可通过现有方法制备得到。
实施例1
本实施例提供了一种可改善肝功能并预防骨质疏松的天然组合物,原料包括:以重量百分比计,柴胡提取物20%、当归提取物15%、香附提取物 20%、陈皮提取物15%、栀子提取物5%、玛咖提取物15%和甘草提取物10%。
所述柴胡提取物中柴胡皂苷含量≥100mg/g,制备方法为:
取干燥的柴胡适量,与水以质量体积比1:9的比例混合,45℃回流提取4小时,水提取液减压浓缩成膏状,用60%乙醇溶解,减压浓缩干燥即得柴胡提取物。
所述当归提取物中当归多糖含量≥200mg/g,制备方法为:
取干燥的当归适量,粉碎,与蒸馏水以质量体积比1:8的比例混合, 80℃回流提取4小时,提取液减压浓缩至1/10体积,加入适量95%乙醇至醇浓度为65%,过滤后收集滤渣,干燥即得当归提取物。
所述香附提取物中多糖含量≥200mg/g,制备方法为:
取干燥的香附适量,粉碎,与水以质量体积比1:8的比例浸泡2.5h, 60℃回流提取4小时,减压浓缩后干燥即得当归提取物。
所述陈皮提取物中总黄酮含量≥50mg/g,制备方法为:
取陈皮适量,与乙醇以质量体积比1:8的比例混合,80℃回流提取3 小时,加入等体积乙酸乙酯萃取,所得乙酸乙酯相减压浓缩,干燥后即得陈皮提取物。
所述栀子提取物中栀子苷含量≥100mg/g,制备方法为:
取栀子果实粉末,加石油醚在90℃下浸泡24h脱脂,过滤后滤渣与 95%乙醇以质量体积比1:8的比例混合,回流提取4h,减压浓缩至浸膏,浸膏用蒸馏水溶解,搅拌,静置3h,过滤,所得上清液减压浓缩干燥后即得栀子提取物。
所述玛咖提取物中玛咖酰胺含量≥40mg/g,制备方法为:
取干燥的玛咖适量,与乙醇以质量体积比1:7的比例混合,超声提取 3小时,醇提取液50℃减压浓缩至浸膏,浸膏干燥即得玛咖提取物。
所述甘草提取物含甘草酸≥400mg/g,制备方法为:
取干燥的甘草适量,与蒸馏水以质量体积比1:10的比例混合,90℃回流提取4小时,提取液浓缩至原体积的1/5,过滤,滤液加浓盐酸调pH至3,静置8小时,过滤,滤渣用适量蒸馏水洗涤两次,滤渣干燥即得甘草提取物。
将上述提取得到的柴胡提取物、当归提取物、香附提取物、陈皮提取物、栀子提取物、玛咖提取物和甘草提取物按比例混合,即得可改善肝功能并预防骨质疏松的天然组合物。
实施例2
本实施例提供了一种可改善肝功能并预防骨质疏松的天然组合物,原料包括:以重量百分比计,柴胡提取物10%、当归提取物20%、香附提取物 20%、陈皮提取物15%、栀子提取物5%、玛咖提取物10%和甘草提取物5%。其制备方法与实施例1基本一致。
实施例3
本实施例提供了一种可改善肝功能并预防骨质疏松的天然组合物,原料包括:以重量百分比计,柴胡提取物20%、当归提取物10%、香附提取物 15%、陈皮提取物10%、栀子提取物15%、玛咖提取物15%和甘草提取物15%。其制备方法与实施例1基本一致。
实施例4
本实施例提供了一种可改善肝功能并预防骨质疏松的天然组合物,原料包括:以重量百分比计,柴胡提取物20%、当归提取物10%、香附提取物 20%、陈皮提取物15%、栀子提取物10%、玛咖提取物10%和甘草提取物15%。其制备方法与实施例1基本一致。
实施例5
本实施例提供了一种可改善肝功能并预防骨质疏松的天然组合物,原料包括:以重量百分比计,柴胡提取物15%、当归提取物20%、香附提取物 15%、陈皮提取物5%、栀子提取物15%、玛咖提取物15%和甘草提取物15%。其制备方法与实施例1基本一致。
对比例1
本对比例提供了一种天然组合物,原料为:以重量份数计,柴胡20 份、当归15份、白术20份、陈皮15份、郁金5份、玛咖15份和甘草10份。
按上述配比称取柴胡、当归、白术、陈皮、郁金、玛咖和甘草后混合配药,研磨,加入与药物质量体积比为1:5的水后煎煮两次,将两次的煎煮液合并。
对比例2
本对比例提供了一种天然组合物,原料为:以重量份数计,柴胡20 份、白术15份、香附20份、陈皮15份、栀子5份、大枣15份和甘草10份。
按上述配比称取柴胡、白术、陈皮、栀子、大枣和甘草后混合配药,研磨,加入与药物质量体积比为1:5的水后煎煮两次,将两次的煎煮液合并。
实施例6
本实施例对实施例1-3和对比例1、2所提供的五组天然组合物的功效进行了测评,具体过程如下:
1.分组与给药
选取雌性SD大鼠为试验对象,体重180-200g,饲养于SPF级动物房,室温20-22℃,相对湿度为60%-70%,灯照周期为12h(7:00-9:00灯照,19:00-7:00黑暗),适应性喂养5d后,随机分为各实施例组、对比例组、模型组与空白组,每组10只。各组大鼠每日按常规方法分笼喂养,各实施例组和对比例组以3g/kg·BW剂量灌胃,模型组与空白组灌胃蒸馏水。
2.模型制作
各实施例组、对比例组与模型组连续4周每日腹腔注射CCl4构建肝损伤模型;空白组注射蒸馏水。
3.各实施例组对肝损伤大鼠肝功能的影响
给药结束后,分离血清进行肝脏功能相关指标测定。采用双缩脲终点法测定血清总蛋白(TP)含量,采用溴甲酚绿终点法测定血清白蛋白(ALB)含量,球蛋白(GLB)为TP与ALB差值;采用速率法测定丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)活力。采用SPSS 16.0软件进行数据分析,结果以x±s 表示,组间比较采用单因素方差分析及最小显著差异法,P<0.05为差异有统计学意义。结果见表1。
表1各实施例组合物对肝损伤大鼠肝功能的影响
注:a表示与空白组比较有显著差异;b表示与模型组比较有显著差异。
ALB减少,说明正常肝细胞逐渐减少,肝细胞合成蛋白、凝血因子功能差,肝脏储备功能减退,同时损伤的肝细胞刺激淋巴系统大量制造GLB,这种变化与肝细胞损伤的严重程度和病损范围呈正比。ALT和AST是最常用的反应肝细胞损伤的指标,其中ALT急剧上升是急性损伤的敏感指标,AST持续升高是慢性损伤的标志。由表1可见,模型组大鼠血清ALB水平下降,GLB和 AST水平上升,ALT急剧上升,说明肝损伤模型构建成功。各实施例组在不同程度上抑制GLB、AST、ALT上升和ALB下降,可以起到保肝护肝作用。各对比例组虽有一定效果但均弱于实施例组。
4.各实施例组对肝损伤大鼠骨质状况的影响
给药结束后处死大鼠,取大鼠双侧股骨小心剔除肌肉及其他组织,其中一侧股骨在双能X线骨密度仪上做骨密度扫描,测出骨密度(g/cm2),一侧股骨测骨长,110℃烘干1小时,称股骨重,再置马弗炉内800℃灰化6小时,灰化结束,冷却称灰重,用浓硝酸提取后测骨灰钙、磷含量。采用SPSS18.0软件进行数据分析,结果以x±s表示,组间比较采用单因素方差分析及最小显著差异法,P<0.05为差异有统计学意义。结果见表2、3。
表2各实施例组合物对肝损伤大鼠股骨骨密度及股骨骨指数的影响
注:a表示与模型组比较有显著差异;b表示与空白组比较有显著差异。
表3各实施例组合物对肝损伤大鼠股骨骨灰分、骨钙、骨磷的影响
注:a表示与模型组比较有显著差异;b表示与空白组比较有显著差异。
由表2和3可见,持续肝损伤结状态可造成大鼠骨密度、骨灰分、骨钙和骨磷含量下降,显示出骨质疏松症状,给予各实施例组合物后,可提高大鼠肝损伤状态的骨骼质量,在一定程度上缓解骨质疏松症状。各对比例组虽有一定效果但均弱于实施例组。
由此可以看出,本发明提供的一种可改善肝功能并预防骨质疏松的中药组合物可有效改善肝功能和骨质疏松症状。
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (10)
1.一种可改善肝功能并预防骨质疏松的中药组合物,其特征在于:组分包括:以质量百分比计,柴胡提取物10~20%、当归提取物10-20%、香附提取物10~20%、陈皮提取物5~15%、栀子提取物5~15%、玛咖提取物10~20%和甘草提取物5~15%。
2.如权利要求1所述的可改善肝功能并预防骨质疏松的中药组合物,其特征在于:所述柴胡提取物中柴胡皂苷含量≥100mg/g;所述当归提取物中当归多糖含量≥200mg/g;所述香附提取物中多糖含量≥200mg/g;所述陈皮提取物中总黄酮含量≥50mg/g;所述栀子提取物中栀子苷含量≥100mg/g;所述玛咖提取物中玛咖酰胺含量≥40mg/g;所述甘草提取物中甘草酸含量≥400mg/g。
3.权利要求1或2所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:以柴胡、当归、香附、陈皮、栀子、玛咖和甘草为原料,对原料分别进行提取,将提取得到的柴胡提取物、当归提取物、香附提取物、陈皮提取物、栀子提取物、玛咖提取物和甘草提取物按比例混合。
4.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述柴胡提取物的提取方法包括:取干燥的柴胡,与水以质量体积比1:8~10的比例混合,40~50℃回流提取3~5小时,水提取液减压浓缩成膏状,用乙醇溶解,减压浓缩干燥即得柴胡提取物。
5.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述当归提取物的提取方法包括:取干燥的当归,粉碎,与蒸馏水以质量体积比1:5~10的比例混合,70~90℃回流提取3~5小时,提取液减压浓缩至1/9~1/11体积,加入乙醇至醇浓度为65%,过滤后收集滤渣,干燥即得当归提取物。
6.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述香附提取物的提取方法包括:取干燥的香附,粉碎,与水以质量体积比1:5~10的比例浸泡2~3h,50~70℃回流提取3~5小时,减压浓缩后干燥即得香附提取物。
7.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述陈皮提取物的提取方法包括:将陈皮与乙醇以质量体积比1:5~10的比例混合,70~90℃回流提取2~4小时,加入等体积乙酸乙酯萃取,所得乙酸乙酯相减压浓缩,干燥后即得陈皮提取物。
8.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述栀子提取物的提取方法包括:取栀子果实粉末,加石油醚在88~92℃下浸泡22~26h脱脂,过滤后滤渣与乙醇以质量体积比1:5~10的比例混合,回流提取3~5h,减压浓缩得浸膏,浸膏用蒸馏水溶解,搅拌,静置2~4h,过滤,所得上清液减压浓缩干燥后即得栀子提取物。
9.如权利要求3所述的可改善肝功能并预防骨质疏松的中药组合物的制备方法,其特征在于:所述玛咖提取物的提取方法包括:取干燥的玛咖,与乙醇以质量体积比1:5~10的比例混合,超声提取2~4小时,醇提取液于45~55℃减压浓缩得浸膏,浸膏干燥即得玛咖提取物;所述甘草提取物的提取方法包括:取干燥的甘草,与蒸馏水以质量体积比1:9~11的比例混合,88~92℃回流提取3.5~4.5小时,提取液浓缩至原体积的1/4~1/6,过滤,滤液加浓盐酸调pH至2~4,静置7~9小时,过滤,滤渣用蒸馏水洗涤,滤渣干燥即得甘草提取物。
10.权利要求1或2所述的可改善肝功能并预防骨质疏松的中药组合物在制备改善肝功能并预防骨质疏松症药物中的应用,其特征在于:所述改善肝功能并预防骨质疏松症药物用于抑制血清球蛋白、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶上升和白蛋白下降,提高骨密度、骨矿物质含量。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910338069.8A CN110237166A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910338069.8A CN110237166A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110237166A true CN110237166A (zh) | 2019-09-17 |
Family
ID=67883273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910338069.8A Pending CN110237166A (zh) | 2019-04-25 | 2019-04-25 | 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110237166A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111166789A (zh) * | 2019-11-28 | 2020-05-19 | 湖南中医药大学 | 夏枯草花提取物在制备治疗肝损伤的药品中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695684A (zh) * | 2005-05-26 | 2005-11-16 | 赵晓昂 | 复方栀豉甘总提取物及其制剂和用途 |
CN101229304A (zh) * | 2008-02-25 | 2008-07-30 | 北京金方华医药科技有限公司 | 柴胡疏肝散口服制剂及其制备方法 |
CN101254247A (zh) * | 2008-03-25 | 2008-09-03 | 深圳力瑞医药科技有限公司 | 一种具有抗抑郁、抗焦虑作用的药物组合物及其制备方法 |
CN103585138A (zh) * | 2013-11-19 | 2014-02-19 | 武汉华士特工业生物技术开发有限公司 | 天然玛咖酰胺化合物在制备增加骨密度产品中的应用 |
CN103800487A (zh) * | 2014-02-25 | 2014-05-21 | 湖南天济草堂制药有限公司 | 丹栀逍遥药物及制备方法以及片剂 |
-
2019
- 2019-04-25 CN CN201910338069.8A patent/CN110237166A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695684A (zh) * | 2005-05-26 | 2005-11-16 | 赵晓昂 | 复方栀豉甘总提取物及其制剂和用途 |
CN101229304A (zh) * | 2008-02-25 | 2008-07-30 | 北京金方华医药科技有限公司 | 柴胡疏肝散口服制剂及其制备方法 |
CN101254247A (zh) * | 2008-03-25 | 2008-09-03 | 深圳力瑞医药科技有限公司 | 一种具有抗抑郁、抗焦虑作用的药物组合物及其制备方法 |
CN103585138A (zh) * | 2013-11-19 | 2014-02-19 | 武汉华士特工业生物技术开发有限公司 | 天然玛咖酰胺化合物在制备增加骨密度产品中的应用 |
CN103800487A (zh) * | 2014-02-25 | 2014-05-21 | 湖南天济草堂制药有限公司 | 丹栀逍遥药物及制备方法以及片剂 |
Non-Patent Citations (2)
Title |
---|
段柯兆,等: "《玛咖》", 31 October 2014, 云南科技出版社 * |
高洁生,等: "养肝解郁方对实验性肝损伤大鼠单核巨噬细胞的影响", 《中西医结合肝病杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111166789A (zh) * | 2019-11-28 | 2020-05-19 | 湖南中医药大学 | 夏枯草花提取物在制备治疗肝损伤的药品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guo et al. | Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs | |
KR100586813B1 (ko) | 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는 치료용 건강식품 | |
JP2001514650A (ja) | 精油組成物 | |
CN104721678A (zh) | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 | |
CN101269170B (zh) | 一种治疗更年期综合征的药物及其制备方法 | |
CN103372051B (zh) | 一种调节血脂的红曲葛根药物组合及其制备方法 | |
CN104474135B (zh) | 一种对化学性肝损伤具有辅助保护功能的药物组合物 | |
CN103372073A (zh) | 一种调节血脂的红曲山楂药物组合及其制备方法 | |
CN110237166A (zh) | 一种可改善肝功能并预防骨质疏松的天然组合物及其制备方法 | |
JP2003171303A (ja) | 特定植物含有組成物と該組成物を有効成分とする医薬品と保健用食品 | |
CN105079773A (zh) | 一种中药组合物及其用途 | |
CN102293923B (zh) | 一种藏药组合物在制备预防和治疗骨质疏松药物中的应用 | |
CN102114070B (zh) | 一种治疗骨质疏松的复方中药及其制备方法 | |
CN1814153B (zh) | 一种预防和治疗乳腺癌的药物组合物及其制备方法 | |
CN104257839B (zh) | 一种具有降糖降脂保护血管内皮作用的中药组合物及其制备方法 | |
CN106853021A (zh) | 防治慢性肾脏病的中药组合物及其制备方法和应用 | |
CN103372040B (zh) | 一种调节血脂的红曲川芎药物组合及其制备方法 | |
CN111617128A (zh) | 一种具有促进骨质健康作用的中药复方组合物及其制备方法与应用 | |
CN104027433B (zh) | 一种中药组合物及其制备方法与临床制剂 | |
CN106110048A (zh) | 一种治疗痤疮的药物组合物 | |
CN102599501B (zh) | 降脂护肝的保健食品红洋胶囊或片剂 | |
CN105434799A (zh) | 一种制备治疗老年性骨折的中药组合物的方法 | |
CN104173681B (zh) | 一种治疗去势抵抗性前列腺癌的中草药组合物 | |
CN107095979A (zh) | 一种适用于治疗高血脂症的中药组合物、其制备方法和应用 | |
CN108210873B (zh) | 一种增加雌激素的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |